ENDOLOGIX INC /DE/ Form 4 July 31, 2013

# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**OMB** 

**OMB APPROVAL** 

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

**SECURITIES** 

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Machek James Edward

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol ENDOLOGIX INC /DE/ [ELGX]

(First) (Middle) (Last)

3. Date of Earliest Transaction

Director 10% Owner

(Check all applicable)

11 STUDEBAKER

(Month/Day/Year)

07/29/2013

Other (specify

X\_ Officer (give title below) below) VP-Research & Development

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line) \_X\_ Form filed by One Reporting Person

Form filed by More than One Reporting Person

**IRVINE, CA 92618** 

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year) Execution Date, if

3. Code (Month/Day/Year)

TransactionAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 8)

4. Securities

5. Amount of Securities Beneficially Owned Following Reported

6. Ownership 7. Nature of Form: Direct Indirect (D) or Indirect (I) (Instr. 4)

Beneficial Ownership (Instr. 4)

(9-02)

(A) or

(D)

Amount

Transaction(s) (Instr. 3 and 4) Price

Common Stock

07/29/2013

07/29/2013

4,000 A (1)(2)

Code V

A \$0 11,189 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: ENDOLOGIX INC /DE/ - Form 4

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number of on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercise Expiration Date (Month/Day/Y | e                  | 7. Title and A<br>Underlying S<br>(Instr. 3 and | Securities                          |
|-----------------------------------------------------|-----------------------------------------------------------------------|--------------------------------------|-------------------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------------------|-----------------------------------------------|--------------------|-------------------------------------------------|-------------------------------------|
|                                                     |                                                                       |                                      |                                                             | Code V                                 | (A) (D)                                                                                    | Date<br>Exercisable                           | Expiration<br>Date | Title                                           | Amount<br>or<br>Number<br>of Shares |
| Option to Purchase                                  | \$ 15.18                                                              | 07/29/2013                           | 07/29/2013                                                  | A                                      | 19,217<br>(3)                                                                              | 07/29/2014                                    | 07/29/2023         | Common<br>Stock                                 | 19,217                              |

# **Reporting Owners**

| Reporting Owner Name / Address | Relationships |             |         |       |  |  |
|--------------------------------|---------------|-------------|---------|-------|--|--|
|                                | Director      | 100% Oxynor | Officer | Other |  |  |

Machek James Edward 11 STUDEBAKER IRVINE, CA 92618

VP-Research & Development

#### **Signatures**

James E. Machek by Leonard M. Greenstein, Attorney-in-Fact for Reporting Person.

07/31/2013

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 100% vesting upon a full market launch of a certain product in development, if it occurs by December 31,2014.
- (2) 100% cliff vesting to occur July 29, 2017 if milestone described in (1) is not met.
- (3) 25% of the options vest on first anniversary and the remaining 75% of options vest on a straight-line basis over the following thirty-six months, for full vesting by July 29, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2